A compound of Formula I: and N-oxides, pharmaceutically acceptable salts, solvates, and stereochemical isomers thereof, wherein: R 1 is mono or bicyclic heteroaryl, or pyridin-2-on-yl,wherein said heteroaryl is optionally substituted with one, two or three R a substituents; wherein R a is -NH 2, halogen, alkoxy, alkylether, alkylthio, alkylsulfonyl, phenylsulfonyl, heteroarylsulfonyl, heterocyclylsulfonyl, -SO 2 NH 2, alkylsulfonamide, alkyl, aminoalkyl, alkylamino, phenyl, heteroaryl, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclyl, -CO 2 -alkyl, -C -R b, -C alkyl-morpholinyl, -C alkyl-piperidinyl, -C alkyl-piperazinyl, -C alkyl-N'-methyl piperazinyl, -C alkyl-R b, -C NH-C alkyl-R b, or -C NR c R d; wherein R b is heterocyclyl, alkylsulfonyl, -SO 2 NH 2, alkylsulfonamide, -OH, -Oalkyl, -NH 2, -NHalkyl, or -N(alkyl) 2; R c and R d are independently selected from: H, phenyl, heteroaryl, or C 1-6 alkyl, wherein said C 1-6 alkyl may optionally be substituted with one substituent selected from: -N(CH 3) 2, morpholinyl, piperidinyl, piperazinyl, N-methyl piperazinyl, alkylsulfonyl, -SO 2 NH 2, alkylsulfonamide, hydroxyl, and alkoxy; or R c and R d together may form a 5 to 7 membered heterocyclic ring, optionally containing a second heteromoiety selected from O, NH, N(alkyl), SO, SO 2, or S; wherein said R c -R d heterocyclic ring is optionally substituted with alkyl, -SO 2 alkyl, or -C alkyl; A is a ring selected from the group consisting of: phenyl, mono or bicyclic heteroaryl, 3-(4-methoxy-benzyl)-3H-quinazolin-4-on-6-yl, quinazolin-4-on-6-yl, and benzo-fused heterocyclyl; wherein said phenyl, heteroaryl, or benzo-fused heterocyclyl are optionally substituted with one to three substituents independently selected from the group consisting of: -OH, alkyl, phenyl, heteroaryl, alkoxy, -CN, halogen, nitro, -NH 2, -N(CH 3) 2, -NHC NHC 1-6 alkyl, and -NHC C 1-6 alkyl; R 5 and R 6 are F; and R 7 and R 8 are H, halogen or C 1-6 alkyl. R 1 is mono or bicyclic heteroaryl, or pyridin-2-on-yl,wherein said heteroaryl is optionally substituted with one, two or three R a substituents; wherein R a is -NH 2, halogen, alkoxy, alkylether, alkylthio, alkylsulfonyl, phenylsulfonyl, heteroarylsulfonyl, heterocyclylsulfonyl, -SO 2 NH 2, alkylsulfonamide, alkyl, aminoalkyl, alkylamino, phenyl, heteroaryl, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclyl, -CO 2 -alkyl, -C -R b, -C alkyl-morpholinyl, -C alkyl-piperidinyl, -C alkyl-piperazinyl, -C alkyl-N'-methyl piperazinyl, -C alkyl-R b, -C NH-C alkyl-R b, or -C NR c R d; wherein R b is heterocyclyl, alkylsulfonyl, -SO 2 NH 2, alkylsulfonamide, -OH, -Oalkyl, -NH 2, -NHalkyl, or -N(alkyl) 2; R c and R d are independently selected from: H, phenyl, heteroaryl, or C 1-6 alkyl, wherein said C 1-6 alkyl may optionally be substituted with one substituent selected from: -N(CH 3) 2, morpholinyl, piperidinyl, piperazinyl, N-methyl piperazinyl, alkylsulfonyl, -SO 2 NH 2, alkylsulfonamide, hydroxyl, and alkoxy; or R c and R d together may form a 5 to 7 membered heterocyclic ring, optionally containing a second heteromoiety selected from O, NH, N(alkyl), SO, SO 2, or S; wherein said R c -R d heterocyclic ring is optionally substituted with alkyl, -SO 2 alkyl, or -C alkyl; wherein R a is -NH 2, halogen, alkoxy, alkylether, alkylthio, alkylsulfonyl, phenylsulfonyl, heteroarylsulfonyl, heterocyclylsulfonyl, -SO 2 NH 2, alkylsulfonamide, alkyl, aminoalkyl, alkylamino, phenyl, heteroaryl, cyano, alkenyl, alkynyl, cycloalkyl, heterocyclyl, -CO 2 -alkyl, -C -R b, -C alkyl-morpholinyl, -C alkyl-piperidinyl, -C alkyl-piperazinyl, -C alkyl-N'-methyl piperazinyl, -C alkyl-R b, -C NH-C alkyl-R b, or -C NR c R d; wherein R b is heterocyclyl, alkylsulfonyl, -SO 2 NH 2, alkylsulfonamide, -OH, -Oalkyl, -NH 2, -NHalkyl, or -N(alkyl) 2; R c and R d are independently selected from: H, phenyl, heteroaryl, or C 1-6 alkyl, wherein said C 1-6 alkyl may optionally be substituted with one substituent selected from: -N(CH 3) 2, morpholinyl, piperidinyl, piperazinyl, N-methyl piperazinyl, alkylsulfonyl, -SO 2 NH 2, alkylsulfonamide, hydroxyl, and alkoxy; or R c and R d together may form a 5 to 7 membered heterocyclic ring, optionally containing a second heteromoiety selected from O, NH, N(alkyl), SO, SO 2, or S; wherein said R c -R d heterocyclic ring is optionally substituted with alkyl, -SO 2 alkyl, or -C alkyl; wherein R b is heterocyclyl, alkylsulfonyl, -SO 2 NH 2, alkylsulfonamide, -OH, -Oalkyl, -NH 2, -NHalkyl, or -N(alkyl) 2; R c and R d are independently selected from: H, phenyl, heteroaryl, or C 1-6 alkyl, wherein said C 1-6 alkyl may optionally be substituted with one substituent selected from: -N(CH 3) 2, morpholinyl, piperidinyl, piperazinyl, N-methyl piperazinyl, alkylsulfonyl, -SO 2 NH 2, alkylsulfonamide, hydroxyl, and alkoxy; or R c and R d together may form a 5 to 7 membered heterocyclic ring, optionally containing a second heteromoiety selected from O, NH, N(alkyl), SO, SO 2, or S; wherein said R c -R d heterocyclic ring is optionally substituted with alkyl, -SO 2 alkyl, or -C alkyl; A is a ring selected from the group consisting of: phenyl, mono or bicyclic heteroaryl, 3-(4-methoxy-benzyl)-3H-quinazolin-4-on-6-yl, quinazolin-4-on-6-yl, and benzo-fused heterocyclyl; wherein said phenyl, heteroaryl, or benzo-fused heterocyclyl are optionally substituted with one to three substituents independently selected from the group consisting of: -OH, alkyl, phenyl, heteroaryl, alkoxy, -CN, halogen, nitro, -NH 2, -N(CH 3) 2, -NHC NHC 1-6 alkyl, and -NHC C 1-6 alkyl; R 5 and R 6 are F; and R 7 and R 8 are H, halogen or C 1-6 alkyl.